Rafael Mayoral

Rafael Mayoral

Auto-generated profile, based on publicly available information

Rafael Mayoral

Discovery Biology, Merck & Co., Inc., South San Francisco, California 94080, United States

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2019 in Science
Verified
Journal Article
Closed access
PDF file
BCBhagirath Chaurasia
Bhagirath Chaurasia
TTTrevor S. Tippetts
Trevor S. Tippetts
RMRafael Mayoral Monibas
Rafael Mayoral Monibas
JLJinqi Liu
Jinqi Liu
YLYing Li
Ying Li
SSScott A. Summers
Scott A. Summers
Ceramides in focus: Excess calorie intake can ultimately lead to a metabolic syndrome that interferes with fat or lipid metabolism. There are many different types of lipids, and it has been widely debated which are the true culprits underlying metabolic disorders. Chaurasia et al. report that ceramides are the major contributor to insulin resistance and fatty liver disease (see the Perspective by Kusminski and Scherer). This appears to be caused by the enzyme dihydroceramide desaturase 1 (DES1), which is normally involved in ceramide production by inserting a double bond into the backbone of the molecule. In mice fed a high-fat diet, deletion of DES1 improved glucose and lipid metabolism. Science , this issue p. 386 ; see also p. 319

23 February 2015 in Nature Medicine
Verified
Journal Article
Open access
PDF file
PLPingping Li
Pingping Li
DODa Young Oh
Da Young Oh
GBGautam Bandyopadhyay
Gautam Bandyopadhyay
WLWilliam S Lagakos
William S Lagakos
STSaswata Talukdar
Saswata Talukdar
JOJerrold M Olefsky
Jerrold M Olefsky
Genetic and pharmacological inhibition of the high-affinity LTB4 receptor promotes improved metabolism in obese mice. Insulin resistance results from several pathophysiologic mechanisms, including chronic tissue inflammation and defective insulin signaling. We found that liver, muscle and adipose tissue exhibit higher levels of the chemotactic eicosanoid LTB4 in obese high-fat diet (HFD)–fed mice. Inhibition of the LTB4 receptor Ltb4r1, through either genetic or pharmacologic loss of function, led to an anti-inflammatory phenotype with protection from insulin resistance and hepatic steatosis. In vitro treatment with LTB4 directly enhanced macrophage chemotaxis, stimulated inflammatory pathways, reduced insulin-stimulated glucose uptake in L6 myocytes, and impaired insulin-mediated suppression of hepatic glucose output in primary mouse hepatocytes. This was accompanied by lower insulin-stimulated Akt phosphorylation and higher Irs-1/2 serine phosphorylation, and all of these events were dependent on Gαi and Jnk1, two downstream mediators of Ltb4r1 signaling. These observations elucidate a novel role of the LTB4–Ltb4r1 signaling pathway in hepatocyte and myocyte insulin resistance, and they show that in vivo inhibition of Ltb4r1 leads to robust insulin-sensitizing effects.

28 May 2015 in Diabetes
Verified
Journal Article
Open access
PDF file
JMJoanne C. McNelis
Joanne C. McNelis
YLYun Sok Lee
Yun Sok Lee
RMRafael Mayoral
Rafael Mayoral
RKRik Van Der Kant
Rik Van Der Kant
AJAndrew M.F. Johnson
Andrew M.F. Johnson
JOJerrold M. Olefsky
Jerrold M. Olefsky
The intestinal microbiome can regulate host energy homeostasis and the development of metabolic disease. Here we identify GPR43, a receptor for bacterially produced short-chain fatty acids (SCFAs), as a modulator of microbiota-host interaction. β-Cell expression of GPR43 and serum levels of acetate, an endogenous SCFA, are increased with a high-fat diet (HFD). HFD-fed GPR43 knockout (KO) mice develop glucose intolerance due to a defect in insulin secretion. In vitro treatment of isolated murine islets, human islets, and Min6 cells with (S)-2-(4-chlorophenyl)-3,3-dimethyl-N-(5-phenylthiazol-2-yl)butanamide (PA), a specific agonist of GPR43, increased intracellular inositol triphosphate and Ca2+ levels, and potentiated insulin secretion in a GPR43-, Gαq-, and phospholipase C–dependent manner. In addition, KO mice fed an HFD displayed reduced β-cell mass and expression of differentiation genes, and the treatment of Min6 cells with PA increased β-cell proliferation and gene expression. Together these findings identify GPR43 as a potential target for therapeutic intervention.

1 May 2015 in Molecular Metabolism
Verified
Journal Article
Open access
RMRafael Mayoral
Rafael Mayoral
OOOlivia Osborn
Olivia Osborn
JMJoanne McNelis
Joanne McNelis
AJAndrew M. Johnson
Andrew M. Johnson
DODa Young Oh
Da Young Oh
JOJerrold M. Olefsky
Jerrold M. Olefsky
Adipose tissue is the primary site for lipid deposition that protects the organisms in cases of nutrient excess during obesogenic diets. The histone deacetylase Sirtuin 1 (SIRT1) inhibits adipocyte differentiation by targeting the transcription factor peroxisome proliferator activated-receptor gamma (PPARγ). To assess the specific role of SIRT1 in adipocytes, we generated Sirt1 adipocyte-specific knockout mice (ATKO) driven by aP2 promoter onto C57BL/6 background. Sirt1 (flx/flx) aP2Cre (+) (ATKO) and Sirt1 (flx/flx) aP2Cre (-) (WT) mice were fed high-fat diet for 5 weeks (short-term) or 15 weeks (chronic-term). Metabolic studies were combined with gene expression analysis and phosphorylation/acetylation patterns in adipose tissue. On standard chow, ATKO mice exhibit low-grade chronic inflammation in adipose tissue, along with glucose intolerance and insulin resistance compared with control fed mice. On short-term HFD, ATKO mice become more glucose intolerant, hyperinsulinemic, insulin resistant and display increased inflammation. During chronic HFD, WT mice developed a metabolic dysfunction, higher than ATKO mice, and thereby, knockout mice are more glucose tolerant, insulin sensitive and less inflamed relative to control mice. SIRT1 attenuates adipogenesis through PPARγ repressive acetylation and, in the ATKO mice adipocyte PPARγ was hyperacetylated. This high acetylation was associated with a decrease in Ser273-PPARγ phosphorylation. Dephosphorylated PPARγ is constitutively active and results in higher expression of genes associated with increased insulin sensitivity. Together, these data establish that SIRT1 downregulation in adipose tissue plays a previously unknown role in long-term inflammation resolution mediated by PPARγ activation. Therefore, in the context of obesity, the development of new therapeutics that activate PPARγ by targeting SIRT1 may provide novel approaches to the treatment of T2DM.

14 October 2014 in Diabetes
Verified
Journal Article
Open access
PDF file
HMHidetaka Morinaga
Hidetaka Morinaga
RMRafael Mayoral
Rafael Mayoral
JHJan Heinrichsdorff
Jan Heinrichsdorff
OOOlivia Osborn
Olivia Osborn
NFNiclas Franck
Niclas Franck
DODa Young Oh
Da Young Oh
The current dogma is that obesity-associated hepatic inflammation is due to increased Kupffer cell (KC) activation. However, recruited hepatic macrophages (RHMs) were recently shown to represent a sizable liver macrophage population in the context of obesity. Therefore, we assessed whether KCs and RHMs, or both, represent the major liver inflammatory cell type in obesity. We used a combination of in vivo macrophage tracking methodologies and adoptive transfer techniques in which KCs and RHMs are differentially labeled with fluorescent markers. With these approaches, the inflammatory phenotype of these distinct macrophage populations was determined under lean and obese conditions. In vivo macrophage tracking revealed an approximately sixfold higher number of RHMs in obese mice than in lean mice, whereas the number of KCs was comparable. In addition, RHMs comprised smaller size and immature, monocyte-derived cells compared with KCs. Furthermore, RHMs from obese mice were more inflamed and expressed higher levels of tumor necrosis factor-α and interleukin-6 than RHMs from lean mice. A comparison of the MCP-1/C-C chemokine receptor type 2 (CCR2) chemokine system between the two cell types showed that the ligand (MCP-1) is more highly expressed in KCs than in RHMs, whereas CCR2 expression is approximately fivefold greater in RHMs. We conclude that KCs can participate in obesity-induced inflammation by causing the recruitment of RHMs, which are distinct from KCs and are not precursors to KCs. These RHMs then enhance the severity of obesity-induced inflammation and hepatic insulin resistance.

1 January 2011 in Journal of Hepatology
Verified
Journal Article
Closed access
CGCarmelo García-Monzón
Carmelo García-Monzón
OIOreste Lo Iacono
Oreste Lo Iacono
RMRafael Mayoral
Rafael Mayoral
Águeda González-RodríguezÁgueda González-Rodríguez
Águeda González-Rodríguez
MMMaría E. Miquilena-Colina
María E. Miquilena-Colina
PMPaloma Martín-Sanz
Paloma Martín-Sanz